Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 13/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064918 | 0.98 | DRD2 (0.43) | MEN1KMT2ADRD2GSK3BCYP1A2 | |
| SCHEMBL2064445 | 0.91 | GSK3B (0.41) | GSK3BCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL2065813 | 0.90 | KCNMA1 (0.42) | MEN1KMT2ADRD2GSK3BCYP1A2 | |
| SCHEMBL3661580 | 0.90 | GSK3B (0.44) | GSK3BCYP1A2CYP2D6CYP3A4 | |
| SCHEMBL2065553 | 0.89 | KMT2A (0.43) | MEN1KMT2ADRD2GSK3BCYP1A2 | |
| SCHEMBL2065434 | 0.89 | GSK3B (0.45) | MEN1KMT2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL3662756 | 0.88 | GSK3B (0.44) | GSK3BCYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL3402010 | 0.88 | GSK3B (0.39) | MEN1KMT2AGSK3BCYP1A2CYP2D6 | |
| SCHEMBL2065310 | 0.88 | DRD2 (0.43) | DRD2GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2066169 | 0.88 | POLB (0.49) | MEN1KMT2ADRD2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | claimed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | claimed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | claimed |
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | MEN1 3696/4885KMT2A 1782/4885DRD2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.